List of Excipients in Branded Drug SORBITOL-MANNITOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ICU Medical Inc	SORBITOL-MANNITOL	sorbitol and mannitol	0990-7981	WATER

Sorbitol-Mannitol Excipient Strategy and Commercial Opportunities in Pharmaceuticals

Last updated: August 26, 2026

Sorbitol-mannitol is an excipient platform rather than an active pharmaceutical ingredient or a single FDA-approved drug. Its commercial value is concentrated in orally disintegrating tablets, chewable tablets, powders, granules, sachets, lyophilized products, and taste-masked formulations. The strongest opportunities involve co-processed grades that combine sorbitol’s sweetness and mouthfeel with mannitol’s low hygroscopicity, cooling effect, and compactability.

The principal commercial risks are moisture migration, variable compressibility, gastrointestinal tolerability at high sorbitol exposure, formulation-specific regulatory limits, and the absence of a broad composition patent moat. Differentiation is more likely to come from particle engineering, manufacturing consistency, application data, regulatory files, and supply reliability than from the simple combination of the two polyols.

What is sorbitol-mannitol used for in pharmaceutical formulations?

Sorbitol and mannitol are polyol excipients used as diluents, bulking agents, sweeteners, mouthfeel modifiers, plasticizers, and tonicity-adjusting agents. A combined system can be formulated as a physical blend or as a co-processed material.

Attribute	Sorbitol	Mannitol	Strategic implication
Primary formulation role	Sweetener, filler, humectant, plasticizer	Filler, bulking agent, sweetener, tonicity modifier	Combination supports multifunctional formulations
Hygroscopicity	Relatively hygroscopic	Low hygroscopicity	Mannitol can reduce moisture sensitivity, but does not eliminate sorbitol-driven uptake
Taste	Sweet, mild	Sweet with cooling sensation	Useful for pediatric, chewable, and orally disintegrating products
Tablet compression	Can deform plastically and improve binding	Often provides brittle fracture and acceptable tablet structure	Co-processing can improve compactability and disintegration
Aqueous solubility	High	High, but lower than sorbitol at common temperatures	Both support rapid dissolution
Gastrointestinal effect	Excess intake can cause osmotic laxation	Usually better tolerated at moderate levels	Formulation must control total polyol load
Moisture behavior	Can absorb water and promote stickiness	More moisture-stable	Ratio selection is a central development variable
Typical commercial position	Sweetness and binding	Stability, cooling, bulking	Combined grade can target premium solid-dose applications

Sorbitol and mannitol are listed in the FDA Inactive Ingredient Database for multiple dosage forms and routes, subject to product-specific precedent and maximum historical levels.[1] Their use does not automatically establish approval for every route, strength, combination, or patient population.

What pharmaceutical dosage forms benefit most from sorbitol-mannitol?

Orally disintegrating tablets

Orally disintegrating tablets are the clearest target. Mannitol provides a dry, cooling mouthfeel and relatively low moisture uptake. Sorbitol contributes sweetness, binding, and a smoother oral texture. A properly engineered blend can support direct compression or a granulation process with short disintegration times.

Commercial applications include:

• Antiemetics
• Antihistamines
• Analgesics
• Central nervous system products
• Pediatric medicines
• Geriatric medicines
• Emergency-use products that require administration without water

The most valuable product is unlikely to be a simple powder blend. Drug manufacturers generally seek a grade with controlled particle size, low fines, predictable flow, stable compaction, and consistent sensory performance.

Chewable tablets

Sorbitol-mannitol systems can improve sweetness and reduce the chalky texture associated with some mineral salts, active ingredients, and high-load tablets. The cooling effect of mannitol can improve palatability, although excessive cooling may be undesirable in certain pediatric or flavored products.

The main development issue is tablet hardness. Chewable products need sufficient mechanical strength for packaging and transport while remaining easy to bite. A blend that produces very hard tablets can reduce patient acceptability.

Oral powders, granules, and sachets

The combination can act as a carrier for low-dose drugs, probiotics, vitamins, minerals, and reconstitution products. Flowability and segregation control become critical when the active ingredient has a substantially different density or particle-size distribution.

Sorbitol’s hygroscopicity may create caking and reduced pourability. Mannitol can improve powder stability, but the final system still requires moisture-barrier packaging and water-activity testing.

Lyophilized and rapidly reconstituted products

Mannitol is widely used as a bulking agent in freeze-dried pharmaceuticals. It helps provide cake structure and contributes to an acceptable reconstitution profile. Sorbitol can act as a cryoprotective or lyoprotective component in some systems, but its high amorphous character and moisture sensitivity can complicate cake stability.

A sorbitol-mannitol system for lyophilized biologics requires product-specific studies covering:

• Collapse temperature
• Glass-transition behavior
• Residual moisture
• Reconstitution time
• Protein aggregation
• Visible and subvisible particles
• Container-closure interaction

This is a higher-value opportunity than conventional tablet dilution because customers may accept premium pricing for validated cycle development and biologic compatibility.

Parenteral and ophthalmic formulations

Mannitol has established use in injectable products as a bulking or tonicity-adjusting excipient. Sorbitol also has pharmaceutical use in certain parenteral contexts, but the combined system is more sensitive to route, concentration, impurity profile, endotoxin control, and sterilization requirements.

An injectable-grade commercial strategy requires:

• GMP production appropriate for parenteral use
• Low endotoxin specifications
• Bioburden control
• Tight limits on reducing sugars and related impurities
• Compatibility data with the active ingredient
• Container-closure and sterilization validation
• Regulatory precedent for the intended route

An oral-grade product cannot be repositioned as an injectable excipient without a separate quality and regulatory program.

What formulation problems does sorbitol-mannitol solve?

The primary value proposition is balancing competing excipient properties.

Moisture management

Sorbitol can absorb moisture, particularly when present in amorphous or partially crystalline form. Moisture can cause sticking during compression, loss of flow, recrystallization, tablet softening, and reduced stability for moisture-sensitive active ingredients.

Mannitol generally has lower hygroscopicity and can improve the physical stability of a blend. The benefit depends on:

• Sorbitol-to-mannitol ratio
• Crystalline versus amorphous content
• Particle-size distribution
• Residual moisture
• Relative humidity during manufacture and storage
• Packaging barrier properties

A commercial grade should be supported by dynamic vapor sorption data, water-activity data, and accelerated stability studies.

Compression and tablet robustness

Sorbitol can provide plastic deformation and binding. Mannitol can contribute to a more brittle-compaction profile. A co-processed material may outperform either component alone by improving:

• Tablet tensile strength
• Ejection behavior
• Weight variation
• Friability
• Disintegration
• Direct-compression suitability

These benefits must be demonstrated against established alternatives such as directly compressible mannitol, lactose, microcrystalline cellulose, xylitol, and spray-dried polyol systems.

Taste and mouthfeel

Sorbitol is useful when sweetness and smooth mouthfeel are priorities. Mannitol adds a cooling sensation caused by its dissolution enthalpy. The sensory profile can support product differentiation in pediatric, geriatric, and adherence-sensitive medicines.

The blend is less attractive when the active ingredient has a strong bitterness that requires a dedicated taste-masking system. Polyols improve the base taste but do not replace polymer coating, ion exchange, lipid barriers, or complexation where the active has high bitterness intensity.

What sorbitol-mannitol formulations are commercially protectable?

The simple admixture of sorbitol and mannitol is usually a weak patent subject unless the claimed composition has a technically demonstrated and non-obvious result. Stronger opportunities arise from defined material attributes and use cases.

Composition claims

Potential claim variables include:

• Sorbitol-to-mannitol weight ratio
• Crystalline and amorphous fractions
• Moisture content
• Specific surface area
• Particle-size distribution
• Bulk and tapped density
• Degree of agglomeration
• Residual solvent or impurity profile
• X-ray diffraction pattern
• Differential scanning calorimetry profile

A composition claim is stronger when the material has a narrow, reproducible specification and produces an unexpected result, such as substantially improved tablet strength at a defined disintegration time.

Process claims

Manufacturing claims may cover:

• Spray drying
• Fluid-bed granulation
• Melt processing
• Controlled crystallization
• Wet granulation
• Dry granulation
• Coating or agglomeration
• Sequential deposition of one polyol onto the other
• Controlled drying to achieve a target solid-state profile

Process protection can be commercially useful even when composition claims are vulnerable. It may be difficult for a competitor to reproduce the same particle architecture without using a similar process.

Method-of-use claims

Use claims may target:

• Direct compression of orally disintegrating tablets
• Taste masking
• Improved disintegration under low-liquid conditions
• Reduced tablet capping or sticking
• Improved stability for moisture-sensitive actives
• Improved reconstitution of lyophilized products
• Pediatric or geriatric administration

Method claims are product-specific and may be difficult to enforce against an excipient supplier unless the supplier has direct knowledge of the customer’s formulation.

Patent landscape and Orange Book status

Sorbitol-mannitol itself has no single identifiable Orange Book listing because the term describes excipient technology, not an approved active drug product.[2] FDA Orange Book patents are generally listed for approved drug products and may cover the active ingredient, formulation, method of use, or drug-device combination.

The relevant patent landscape normally contains:

1. Excipient composition patents
2. Co-processing and particle-engineering patents
3. Finished drug-product formulation patents
4. Taste-masking patents
5. Orally disintegrating tablet patents
6. Lyophilization and reconstitution patents
7. Manufacturing and crystallization patents

A Paragraph IV challenge would arise against a listed patent for a specific drug product, not against sorbitol-mannitol as a generic excipient category. Excipient suppliers may be exposed indirectly if their material is incorporated into a drug product covered by a formulation or method patent.

When does sorbitol-mannitol lose exclusivity?

Sorbitol-mannitol has no universal drug exclusivity date. Exclusivity depends on the individual patent, regulatory filing, and formulation.

For a finished drug product, relevant dates may include:

Protection type	Typical legal relevance
Composition-of-matter patent	Usually the strongest protection for the active ingredient
Formulation patent	May protect a specific sorbitol-mannitol ratio, dosage form, or release profile
Method-of-use patent	May protect treatment of a defined disease or patient group
Process patent	May protect manufacture of the excipient or drug product
FDA New Chemical Entity exclusivity	Applies to qualifying active ingredients, not the excipient itself
Orphan-drug exclusivity	Applies to the approved drug indication, not the excipient platform
Pediatric exclusivity	Can add six months to certain existing protections
Data exclusivity for biologics	Applies to the biologic product, not a conventional excipient

A generic manufacturer can generally use sorbitol or mannitol as an excipient if its finished product does not infringe valid patents and satisfies FDA quality and bioequivalence requirements. The fact that an excipient is present in an originator product does not itself create exclusivity.

How strong is the patent estate for sorbitol-mannitol technology?

The patent estate is usually moderate to weak at the generic-material level and potentially strong at the engineered-grade level.

Patent strategy	Expected strength	Commercial assessment
Broad claim to sorbitol plus mannitol	Low	Vulnerable to prior-art and obviousness attacks
Narrow ratio and particle-size claim	Moderate	Stronger if tied to reproducible performance
Defined solid-state or crystalline structure	Moderate to high	Useful when analytical fingerprinting is reliable
Spray-drying or co-processing process	Moderate	Can create manufacturing barriers
ODT application claim	Moderate	Depends on unexpected disintegration, hardness, or taste results
Injectable-grade use	Moderate to high	Regulatory qualification raises entry barriers
Finished-drug formulation claim	High in selected cases	May protect a specific commercial product
Trade-secret manufacturing know-how	High operational value	Difficult for competitors to detect or challenge

The most defensible commercial strategy combines a narrow patent portfolio with trade secrets covering feed concentration, drying conditions, seed loading, residence time, humidity control, milling, and packaging.

Which companies are potential customers and competitors?

The customer base includes excipient distributors, generic pharmaceutical companies, branded drug manufacturers, contract development and manufacturing organizations, and biologics developers.

Customer segments

• ODT and chewable-tablet developers
• Pediatric medicine manufacturers
• Generic manufacturers seeking direct-compression excipients
• Consumer-health companies producing chewable supplements
• Lyophilized injectable developers
• Biologic manufacturers using bulking or stabilizing systems
• Contract manufacturers requiring validated excipient supply

Competitive alternatives

Sorbitol-mannitol competes with:

• Directly compressible mannitol
• Spray-dried mannitol
• Sorbitol grades
• Xylitol
• Lactose monohydrate
• Anhydrous lactose
• Microcrystalline cellulose
• Isomalt
• Maltitol
• Co-processed cellulose-based excipients
• Mannitol-crospovidone or mannitol-starch systems

The product must win on a defined performance metric. “Natural sweetness” or “polyol combination” is unlikely to justify a premium without data on compression, stability, sensory performance, or process yield.

What regulatory status applies to sorbitol-mannitol?

United States

Sorbitol and mannitol are recognized pharmaceutical excipients with FDA inactive-ingredient precedent. The regulatory question is not whether the substances are generally known, but whether the proposed grade, amount, route, and dosage form are supported by prior use and appropriate quality controls.[1]

Drug manufacturers must address:

• Identity and assay
• Related substances
• Water content
• Microbial limits
• Residual solvents, where applicable
• Elemental impurities
• Particle-size distribution
• Microbial endotoxin limits for parenteral use
• Nitrosamine risk where relevant to the manufacturing process
• Supplier qualification and change control

European Union

European pharmaceutical use generally relies on the applicable European Pharmacopoeia monographs, excipient quality documentation, and product-specific assessment by national or European regulators.[3] An excipient supplier seeking broad commercial adoption should maintain an appropriate active substance master file or excipient support package where applicable, together with change-notification procedures.

Japan and other markets

Japanese Pharmacopoeia, Chinese Pharmacopoeia, and other national standards may apply depending on the market. Global manufacturers value harmonized specifications, multilingual documentation, audit readiness, and consistent batch release across sites.

What manufacturing barriers affect commercial entry?

The principal barriers are operational rather than chemical.

Critical quality attributes

A marketable grade should control:

• Particle-size distribution
• Bulk density
• Tapped density
• Flow rate
• Compressibility
• Compactability
• Moisture content
• Water activity
• Crystallinity
• Polymorphic form
• Dissolution behavior
• Microbial quality
• Residual solvents
• Heavy metals and elemental impurities

Co-processing introduces scale-up risk. A laboratory blend may perform well while a commercial dryer produces segregation, broad particle-size distribution, or inconsistent amorphous content.

Supply-chain requirements

Pharmaceutical customers normally expect:

• Multiple qualified manufacturing sites or a credible business-continuity plan
• Long-term raw-material controls
• Formal change notification
• Batch-to-batch comparability
• Stability data
• Regulatory support
• Technical troubleshooting
• Customer-specific formulation assistance

A supplier that offers only commodity powder and a certificate of analysis will compete primarily on price. A supplier with formulation laboratories and application data can pursue higher margins.

What commercial opportunities have the highest value?

Premium direct-compression grade

A high-functionality grade for ODTs and chewables is the most accessible opportunity. The product should demonstrate lower lubricant sensitivity, improved tablet tensile strength, rapid disintegration, and acceptable sensory performance.

Pediatric formulation platform

A validated sorbitol-mannitol platform can support low-dose pediatric medicines, multiparticulates, granules, and taste-masked products. Pediatric applications may support higher pricing because taste, dose flexibility, and administration without water are important product attributes.

Lyophilization grade

A product designed for freeze-dried biologics and injectables can command higher prices, but regulatory and technical requirements are substantially greater. The commercial case depends on reproducible cake structure, rapid reconstitution, and compatibility with proteins and peptides.

Custom co-processing

Pharmaceutical companies may pay for customer-specific grades optimized for a particular active ingredient, tablet press, compression force, or packaging format. Customization creates switching costs and may support joint patent filings.

Regulatory and formulation services

The strongest margin may come from a package combining excipient supply, formulation development, stability support, and regulatory documentation. This model positions the supplier as a development partner rather than a bulk-material vendor.

What generic entry risks exist for sorbitol-mannitol formulations?

Generic entry risk is high when the product uses standard sorbitol or mannitol and has no meaningful formulation differentiation. Risk declines when the originator relies on:

• A narrow, patented co-processed grade
• A protected ODT matrix
• A specific taste-masking architecture
• A defined particle-size and solid-state profile
• A proprietary manufacturing process
• A formulation patent linked to a clinically meaningful performance advantage

A generic applicant may design around a claimed ratio, replace one polyol, use a different co-processing route, or qualify a separate supplier. The practical question is whether the excipient materially affects bioequivalence, dissolution, stability, or manufacturability.

How does sorbitol-mannitol compare with mannitol alone?

Criterion	Sorbitol-mannitol	Mannitol alone
Sweetness	Usually stronger or more rounded	Sweet with pronounced cooling effect
Moisture sensitivity	Higher risk due to sorbitol	Generally lower
Mouthfeel	Smooth and sweet	Dry, cooling, potentially chalky
Direct compression	Potentially improved through co-processing	Depends heavily on grade
Formulation flexibility	Broad for oral products	Strong for ODTs and lyophilized products
Regulatory simplicity	Requires justification for combination and grade	Extensive established precedent
Patent opportunity	Higher for engineered co-processed materials	Often concentrated in specialized grades
Supply cost	May be higher than commodity mannitol	Broad range by grade
Best commercial use	Differentiated oral and custom formulations	Standard ODT, injectable, and lyophilized applications

Mannitol alone is usually easier to qualify and source. Sorbitol-mannitol becomes more attractive when sensory performance, binding, or custom tablet behavior justifies the added development work.

Key Takeaways

• Sorbitol-mannitol is an excipient platform, not an active pharmaceutical ingredient.
• The strongest applications are ODTs, chewables, pediatric products, oral powders, and selected lyophilized formulations.
• Mannitol contributes low hygroscopicity, cooling sensation, and bulking; sorbitol contributes sweetness, binding, and mouthfeel.
• The main technical risk is moisture-driven instability from sorbitol.
• Broad composition patents are likely to be weak unless supported by narrow material attributes and unexpected performance.
• Particle engineering, co-processing, solid-state control, and manufacturing know-how provide the most credible protection.
• There is no standalone Orange Book listing or Paragraph IV pathway for sorbitol-mannitol as an excipient.
• Commercial differentiation depends on validated performance data, regulatory support, supply reliability, and customer-specific development.
• Premium opportunities include direct-compression grades, pediatric platforms, injectable or lyophilization grades, and custom co-processed materials.
• Generic entry risk is high for commodity excipient use and lower where the finished drug product has enforceable formulation or method patents.

FAQs About Sorbitol-Mannitol Pharmaceutical Excipient Strategy

Is sorbitol-mannitol an FDA-approved drug?

No. Sorbitol and mannitol are pharmaceutical excipients with FDA inactive-ingredient precedent. They are not approved as an active drug under the term “sorbitol-mannitol.”[1]

Can sorbitol-mannitol be used in orally disintegrating tablets?

Yes. The combination can support sweetness, mouthfeel, tablet binding, rapid disintegration, and low-liquid administration. The grade must be evaluated for moisture uptake, compression behavior, and sensory performance.

Is sorbitol-mannitol suitable for injectable products?

Only a specifically qualified pharmaceutical grade should be considered. Injectable use requires route-specific regulatory precedent, endotoxin control, sterility-related controls, impurity testing, and compatibility data.

Can a sorbitol-mannitol excipient be patented?

Potentially. The strongest claims generally cover defined ratios, particle architecture, solid-state properties, manufacturing processes, or demonstrated formulation performance rather than the broad combination alone.

Does sorbitol-mannitol create generic drug exclusivity?

No. The excipient does not create standalone generic exclusivity. Any protection would arise from patents or regulatory exclusivity covering the finished drug product, its formulation, manufacturing process, or method of use.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
3. European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia (11th ed.). Council of Europe.